Guillaume B E Stewart-Jones
Overview
Explore the profile of Guillaume B E Stewart-Jones including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
3602
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cale E, Shen C, Olia A, Radakovich N, Rawi R, Yang Y, et al.
Cell Rep
. 2024 Dec;
43(12):115010.
PMID: 39675002
Antibodies that target the gp120-gp41 interface of the HIV-1 envelope (Env) trimer comprise a commonly elicited category of broadly neutralizing antibodies (bNAbs). Here, we isolate and characterize VRC44, a bNAb...
2.
Loomis R, Lai Y, Sowers S, Fisher B, Derrien-Colemyn A, Ambrozak D, et al.
Proc Natl Acad Sci U S A
. 2024 Nov;
121(47):e2404053121.
PMID: 39527740
Mumps virus (MuV) is a highly contagious paramyxovirus that is endemic in most regions of the world and continues to cause outbreaks even in highly immunized populations. Outbreaks of mumps...
3.
Stewart-Jones G, Elbashir S, Wu K, Lee D, Renzi I, Ying B, et al.
Sci Transl Med
. 2023 Sep;
15(713):eadf4100.
PMID: 37703353
With the success of messenger RNA (mRNA) vaccines against coronavirus disease 2019, strategies can now focus on improving vaccine potency, breadth, and stability. We designed and evaluated domain-based mRNA vaccines...
4.
Sastry M, Changela A, Gorman J, Xu K, Chuang G, Shen C, et al.
J Virol
. 2023 Apr;
97(5):e0160422.
PMID: 37098956
While neutralizing antibodies that target the HIV-1 fusion peptide have been elicited in mice by vaccination, antibodies reported thus far have been from only a single antibody class that could...
5.
Stewart-Jones G, Elbashir S, Wu K, Lee D, Renzi I, Ying B, et al.
bioRxiv
. 2022 Oct;
PMID: 36238717
One Sentence Summary: A domain-based mRNA vaccine, mRNA-1283, is immunogenic and protective against SARS-CoV-2 and emerging variants in mice.
6.
Loomis R, DiPiazza A, Falcone S, Ruckwardt T, Morabito K, Abiona O, et al.
Front Immunol
. 2021 Dec;
12:772864.
PMID: 34956199
Nipah virus (NiV) represents a significant pandemic threat with zoonotic transmission from bats-to-humans with almost annual regional outbreaks characterized by documented human-to-human transmission and high fatality rates. Currently, no vaccine...
7.
Wu K, Choi A, Koch M, Elbashir S, Ma L, Lee D, et al.
Vaccine
. 2021 Nov;
39(51):7394-7400.
PMID: 34815117
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of a global pandemic. Safe and effective COVID-19 vaccines are now available, including mRNA-1273, which has shown 94% efficacy...
8.
Stewart-Jones G, Gorman J, Ou L, Zhang B, Joyce M, Yang L, et al.
Proc Natl Acad Sci U S A
. 2021 Sep;
118(39).
PMID: 34551978
Human metapneumovirus (HMPV) is a major cause of respiratory disease worldwide, particularly among children and the elderly. Although there is no licensed HMPV vaccine, promising candidates have been identified for...
9.
Choi A, Koch M, Wu K, Dixon G, Oestreicher J, Legault H, et al.
J Virol
. 2021 Sep;
95(23):e0131321.
PMID: 34549975
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has led to growing concerns over increased transmissibility and the ability of some variants to partially escape immunity. Sera...
10.
Williams W, Meyerhoff R, Edwards R, Li H, Manne K, Nicely N, et al.
Cell
. 2021 May;
184(11):2955-2972.e25.
PMID: 34019795
Natural antibodies (Abs) can target host glycans on the surface of pathogens. We studied the evolution of glycan-reactive B cells of rhesus macaques and humans using glycosylated HIV-1 envelope (Env)...